Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

Meanwhile, PlutoChain ($PLUTO) could gain attention for its innovative approach to enhancing Bitcoin's capabilities.

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and ...